Delta-Fly Pharma, Inc. (TYO:4598)
Japan · Delayed Price · Currency is JPY 185.00
-5.00 (-2.63%)
Apr 3, 2026, 3:30 PM JST
Delta-Fly Pharma Market Cap
Delta-Fly Pharma has a market cap or net worth of 2.25 billion as of April 2, 2026. Its market cap has decreased by -59.01% in one year.
Market Cap
2.25B
Enterprise Value
2.01B
Revenue
n/a
Ranking
n/a
PE Ratio
n/a
Stock Price
185.00
Market Cap Chart
Since October 12, 2018, Delta-Fly Pharma's market cap has decreased from 21.91B to 2.25B, a decrease of -89.73%. That is a compound annual growth rate of -26.24%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| Apr 3, 2026 | 2.25B | -63.73% |
| Dec 30, 2025 | 6.20B | 18.44% |
| Dec 30, 2024 | 5.24B | -37.32% |
| Dec 29, 2023 | 8.35B | 21.17% |
| Dec 30, 2022 | 6.89B | -14.46% |
| Dec 30, 2021 | 8.06B | 49.71% |
| Dec 30, 2020 | Upgrade Pro | Upgrade Pro |
| Dec 30, 2019 | Upgrade Pro | Upgrade Pro |
| Dec 28, 2018 | Upgrade Pro | Upgrade Pro |
| Oct 12, 2018 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| TMS Co., Ltd. | 6.41B |
| Noile-Immune Biotech | 6.37B |
| Soiken Holdings | 6.36B |
| Kohjin Bio | 6.19B |
| Linical | 5.80B |
| D. Western Therapeutics Institute | 5.06B |
| Ribomic | 4.89B |
| Transgenic Group | 4.28B |